Szabó , ZsuzsannaSEYED PIRAN, SEYED BEHRAD2025-04-242025-04-242025-04-23https://hdl.handle.net/2437/389342This study explores how two proteins, PD-L1 and PD-L2, may help predict treatment results in people with kidney cancer, specifically renal cell carcinoma (RCC). Researchers compared cancer tissue and nearby healthy kidney tissue from 20 patients and found both proteins were expressed more in tumors. Especially in aggressive tumors (Grade 4), PD-L1 and PD-L2 levels were much higher, suggesting a link between these proteins and tumor severity. One case showed unusually high PD-L1 even in a less aggressive tumor, hinting at differences between individual tumors. The findings suggest that targeting both proteins could improve treatment results, especially for high-risk patients. The study supports the use of these proteins to better match patients with the right immune therapy.44enRCCBIOMARKERPD-L1BiologyHozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében.